free

Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks

Nearly Twice as Many Patients Taking Trexima were Migraine FreeCompared to Placebo CHICAGO, June 08, 2007 /PRNewswire/ -- New data from two largetrials show that Trexima, when taken early, was nearly twice aseffective as placebo in eliminating all traditional migrainesymptoms at two and four hours across multiple attacks with justone tablet. The findings will be presented tomorrow at the...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

CHICAGO – June 2, 2007 – Long-term treatment withpegylated interferon alfa-2b in stage III melanoma had asignificant and sustained impact on relapse-free survival (RFS),according to the results of the largest adjuvant trial everconducted in patients with stage III melanoma. Results of the PhaseIII study, led by...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

Presentation at ASCO Plenary Session Reports EORTC 40983 (EPOC)Intergroup Study Results CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Results of therandomized phase III EORTC 40983 Intergroup study, or EPOC study,demonstrate for the first time that peri-operative (pre and postsurgery) FOLFOX4 (Eloxatin(R) (oxaliplatin injection) incombination with a standard chemotherapy regimen for co...

Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients

SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- BSDMedical Corp. announced today that the results of a 340 patientrandomized Phase III clinical trial testing the benefit of addinghyperthermia therapy to chemotherapy were presented at the annualAmerican Society of Clinical Oncology (ASCO) conference underway inChicago, Illinois. According to the results of this clinical study,whic...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

Oncophage Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer

ANAHEIM, Calif.--(BUSINESS WIRE)--May 21, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced additional follow-up data on thecompany's Phase 3 investigational therapeutic cancer vaccineOncophage(R) (vitespen). The end-of-study results, which reflect anadditional 17 months' data collection, showed that in a substantialsubset of patients (n = 362) at intermediate risk for diseaserecurrence,...

Apollo develops needle-free topical vaccine

SYDNEY, April 30, 2007-Australian bio-discovery company ApolloLife Sciences has released results of preliminary trials of itspatented needle-free vaccine technology, which delivers tetanusvaccine transdermally (through the skin) without the need for aninjection. According to Apollo CEO John Priest, the research points the wayto the possibility that flu injections may soon be a thin...

Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for Travelers' Diarrhea Stimulates Immune Response Even at Low Doses

-- Data Gathered to Assist in Design of Future Trials, OtherPrograms -- GAITHERSBURG, Md. and LISBON, Portugal, April 26, 2007/PRNewswire-FirstCall/ -- Iomai Corporation today announced resultsfrom a 400-patient, Phase 2 dose-ranging trial of its patch-basedvaccine for travelers' diarrhea. The trial was conducted to assessthe ability of a range of vaccine doses to generate an immunerespo...

Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients

- As previously announced, primary endpoint not met; plausiblyconfounded by survival benefit of post-study treatment with ERBITUX- NEW YORK, April 16, 2007 /PRNewswire-FirstCall/ -- ImCloneSystems Incorporated and Bristol-Myers Squibb Company todayannounced detailed results from the EPIC study - a randomized,open-label, multi-center Phase III trial - comparing ERBITUX(R)(Cetuximab) plus...